Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute, discusses these side effects and some practical approaches to managing them with educational, medical, behavioral, and lifestyle interventions.
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses the limited sensitivity and specificity of surveillance testing for cancer recurrence and finding a better way to reassure patients about their continuing care.
Jennifer A. Ligibel, MD, of the Dana-Farber Cancer Institute, discusses the physical activity behaviors and weight changes in a study cohort of young women with breast cancer (Abstract 166).
Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, summarizes the main take-home messages of the conference.
Erin Elizabeth Hahn, PhD, MPH, of Kaiser Permanente Southern California, discusses the use of recommended post-treatment services for adolescent and young adult Hodgkin lymphoma survivors (Abstract 107).
Kerri M. Winters-Stone, PhD, of Oregon Health and Science University, discusses the results of her study, which showed that, years after treatment, nearly half of women cancer survivors still have symptoms of chemotherapy-induced peripheral neuropathy. The findings may inform rehabilitative programs to prevent falls and injuries (Abstract 130).
